Milestone Scient Stock Price, News & Analysis

Milestone Scientific (NYSE American: MLSS) received a notice from NYSE American dated October 8, 2025, stating it is not in compliance with Sections 1003(a)(ii) and 1003(a)(iii) of the Company Guide because stockholders' equity was approximately $3.3 million as of June 30, 2025 and the company reported losses in each of the five most recent fiscal years ended December 31, 2024.

The company must file a plan of compliance by November 7, 2025 describing steps to regain compliance by April 8, 2027. Trading of MLSS will continue on NYSE American while the company works to regain compliance; the notice does not affect day-to-day operations or SEC reporting at this time.

Milestone Scientific (NYSE:MLSS), developer of computerized drug delivery instruments, has appointed Dr. Dawood Sayed to its Board of Directors. Dr. Sayed, a Professor of Anesthesiology and Pain Medicine at the University of Kansas Medical Center, brings extensive expertise in interventional pain medicine and neuromodulation.

The appointment strengthens the company's clinical and commercial strategy for its CompuFlo® Epidural System, which recently received Medicare Part B payment coverage under CPT® code 0777T. Dr. Sayed's experience with health system adoption, clinical training, and reimbursement strategy is expected to accelerate MLSS's growth in the interventional pain management market.

Milestone Scientific (NYSE:MLSS), a developer of computerized drug delivery instruments, reported strong Q2 2025 financial results with a 25% revenue increase to $2.3 million. The growth was primarily driven by international dental sales, which more than doubled year-over-year, maintaining a robust 70% gross margin.

The company has strengthened its leadership team with the appointment of Eric Hines as CEO, Jason Papes as SVP of Global Sales and Marketing, and Shanth Thiyagalingam joining the Board of Directors. Despite revenue growth, the company reported an operating loss of $(1.5) million and ended Q2 with $1.3 million in cash and $3.9 million in working capital.

Notable progress includes securing Medicare Part B payment coverage, gaining commercial insurer support for the CompuFlo® Epidural System, and expanding through the Federal Supply Schedule contract.

Milestone Scientific (NYSE:MLSS), a developer of computerized drug delivery instruments for painless and precise injections, has scheduled its Q2 2025 financial results conference call for Friday, August 15th, 2025, at 8:00 AM ET.

The call will discuss Q2 2025 financial performance, corporate progress, and other developments. Investors can access the call via phone (U.S. toll-free: 888-506-0062; International: +1 973-528-0011; Access code: 470429) or webcast. A replay will be available through August 29th, 2025.

Milestone Scientific (NYSE:MLSS), a developer of computerized drug delivery instruments, has appointed Jason Papes as Senior Vice President, Global Head of Sales and Marketing. Papes brings over 30 years of healthcare industry experience, notably as Founder of TEN20 Medical Distribution and executive positions at Stryker Imaging and Brainlab.

The appointment comes at a crucial time as MLSS advances the commercial rollout of its CompuFlo® Epidural System, which recently received Medicare Part B payment rates under CPT® code 0777T. The company is also expanding its dental segment through the STA Single Tooth Anesthesia® System. Papes will be instrumental in scaling both platforms and implementing market access strategies.

Milestone Scientific (NYSE:MLSS), a developer of computerized drug delivery instruments, has appointed Eric C. Hines as its new Chief Executive Officer. Hines brings over 25 years of leadership experience in scaling sales-driven enterprise software companies, most recently serving as President of North America at Ex Libris where he doubled annual revenue from $50M to $100M.

The appointment comes at a crucial time as Milestone Scientific advances its CompuFlo® technology, having secured Medicare Part B payment rates under CPT® code 0777T and initial commercial insurance payments. Hines' experience in healthcare and track record of commercial expansion positions him to drive adoption of the company's technology in medical and dental markets while pursuing new clinical indications and global opportunities.

Milestone Scientific (NYSE:MLSS) has announced the commercial launch of its CompuFlo® Epidural System at The Painless Center in Tenafly, New Jersey. The center is led by Dr. Chi-Shin Jason Chiu, a double board-certified physician in Pain Management and Anesthesiology.

The CompuFlo system leverages the company's proprietary DPS Dynamic Pressure Sensing® technology, providing real-time feedback for accurate epidural space identification. Clinical studies have demonstrated the system's ability to reduce false loss of resistance, minimize complications, and improve epidural procedure success rates.

This deployment is part of Milestone Scientific's broader strategy to expand the adoption of CompuFlo across U.S. and international markets.

Milestone Scientific (NYSE: MLSS) has appointed Shanth Thiyagalingam to its Board of Directors, effective May 14, 2025. Thiyagalingam, currently CEO of PainTEQ, brings over 20 years of global leadership experience in medical devices and pharmaceuticals. This strategic appointment supports Milestone's expansion of its CompuFlo® Epidural System, particularly following recent favorable Medicare Part B payment rates for CPT code 0777T and FSS contract award.

At PainTEQ, Thiyagalingam led the company's growth from startup to market innovator, securing a Category 1 CPT code for the LinQ procedure. His extensive experience includes leadership roles at Abbott, where he managed APAC Neuromodulation operations, Nevro, Stryker, and St. Jude Medical. He holds a Bachelor of Medical Science, Master's in Marketing Management, and MBA.

Milestone Scientific (NYSE: MLSS) reported Q1 2025 financial results with revenue of $2.2 million, showing a slight decrease from the previous year. The company's medical segment demonstrated growth with increased adoption of the CompuFlo® Epidural System. Key developments include favorable Medicare Part B payment rates under CPT code 0777T and a Federal Supply Schedule (FSS) contract award enabling access to federal healthcare facilities. The company secured $800,000 in convertible financing from Board members. Financial highlights include: gross profit of $1.6 million (74% margin), operating loss of $(2.0) million, and net loss of $(2.0) million or $(0.02) per share. Cash position stands at $2.2 million with working capital of $2.4 million.